Source: Eur Respir J 2008; 32: 1283-1288
Disease area: Airway diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Barbier M., Agusti A., Alberti S.. Fluticasone propionate reduces bacterial airway epithelial invasion. Eur Respir J 2008; 32: 1283-1288

Member's Comments

No comment yet.

Related content which might interest you: Airway epithelial inflammatory responses and clinical parameters in COPD Source: Eur Respir J 2003; 22: 94-99 Year: 2003 Fluticasone propionate decreases MUC5AC expression on airway epithelial cells induced by rhinovirus infection in the airway Source: Annual Congress 2011 - Experimental modulation of airway inflammation Year: 2011 Effects of salmeterol/fluticasone propionate (SFC) on airway inflammation in induced sputum in COPD Source: Annual Congress 2005 - Effects of anti-inflammatory drugs on COPD Year: 2005 Influence of large and small dose of fluticasone propionate on clinical symptoms of bronchial asthma, lung function, bronchial hyperreactivity and eosinophilia in induced sputum Source: Eur Respir J 2002; 20: Suppl. 38, 111s Year: 2002 Mast cells in COPD airways: relationship to bronchodilator responsiveness and angiogenesis Source: Eur Respir J 2012; 39: 1361-1367 Year: 2012 The role of small airways in obstructive airway diseases Source: Eur Respir Rev 2011; 20: 23-33 Year: 2011 Effects of fluticasone and ciclesonide on pulmonary function and airway inflammation in stable mild asthmatics Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009 Differential response of COPD bronchial epithelium to LPS in a three-dimensional culture model Source: Annual Congress 2006 - Airway epithelial cells in inflammation Year: 2006 Acute protective effect of inhaled fluticasone on airway hyperresponsiveness to adenosine 5’-monophosphate in asthma but not in chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: Suppl. 48, 442s Year: 2004 Alveolar absorption and systemic bioactivity of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: Suppl. 48, 13s Year: 2004 Comparison of budesonide and fluticasone propionate on COPD macrophage phagocytosis and killing of bacteria Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Differential effects of budesonide and fluticasone propionate on immune defense genes in human bronchial epithelium Source: International Congress 2015 – The immunology of allergic airway disease Year: 2015 Response to fluticasone propionate in controlling airway inflammation in steroid-naïve asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 317s Year: 2006 Airway pathology in asthma Source: Eur Respir J 2001; 18: 18S-23S Year: 2001 Tiotropium inhibits airway inflammation and goblet cell metaplasia in a model of relapsing asthma in mice Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions Year: 2015 Budesonide and fluticasone propionate exertdifferential effects on human bronchial epithelial cells exposed to streptococcus pneumoniae and viral mimetic Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016 Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment Source: Eur Respir J 2006; 27: 964-971 Year: 2006 Proliferation is not increased in airway myofibroblasts isolated from asthmatics Source: Eur Respir J 2008; 32: 362-371 Year: 2008 Tiotropium and fluticasone inhibit rhinovirus-induced mucin production via multiple mechanisms in differentiated airway epithelial cells Source: Virtual Congress 2020 – Host-microbe interactions and their influence on lung disease onset and severity Year: 2020 Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial Source: Eur Respir J 2007; 29: 906-913 Year: 2007